News 06.02.2024 Schlieren / Zurich, Switzerland, February 5, 2024 – Memo Therapeutics AG (or “MTx”), a late-stage biotech company developing best-in-class therapeutic antibodies for viral infections and oncology, announced today that it has strengthened its senior team with the appointments of Kristie B. Clemmer and Dr. Maartje Verschuur as VP Clinical Operations and...
News 04.02.2024 Schlieren (Zurich), February 01, 2024 – LimmaTech Biologics today announced a second closing of its Series A financing, raising an additional USD 3 million from new investor Tenmile, bringing the total raised to USD 40 million (CHF 34,7 million). The funding will be utilized to further advance the company’s proprietary...
News 01.02.2024 Zurich, Switzerland - 31.01.2024 Neurimmune aims to develop aducanumab-based therapeutics that can be subcutaneously administered Neurimmune announced today that it regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid. Aducanumab was granted FDA accelerated approval for the treatment of Alzheimer’s disease. Neurimmune licensed its antibody aducanumab for...
News 01.02.2024 Schlieren (Zurich), Switzerland, January 31, 2024 – Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced clearance of a 510(k) submission from the U.S. Food and Drug Administration (FDA) related to its MagnetOs™ Granules. The Company also announced clearance to market in New Zealand...
News 27.01.2024 Securecell AG has released a new version of Lucullus®. The latest update follows version 23.0.0 and is named version 24.1.0 based on the new version naming convention. With version 24.1.0, many new features were implemented, and a long list of bugs was resolved. The most important changes are: After a thorough...